• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key.

作者信息

den Broeder Nathan, Bouman Chantal A M, Kievit Wietske, van Herwaarden Noortje, van den Hoogen Frank H J, van Vollenhoven Ronald F, Bijlsma Hans W J, van der Maas Aatke, den Broeder Alfons A

机构信息

Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.

Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Ann Rheum Dis. 2019 Jan;78(1):141-142. doi: 10.1136/annrheumdis-2018-213547. Epub 2018 Aug 27.

DOI:10.1136/annrheumdis-2018-213547
PMID:30150367
Abstract
摘要

相似文献

1
Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key.DRESS研究的三年成本效益分析：规范化减量是关键。
Ann Rheum Dis. 2019 Jan;78(1):141-142. doi: 10.1136/annrheumdis-2018-213547. Epub 2018 Aug 27.
2
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
3
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.阿那白滞素治疗成人类风湿关节炎的临床疗效与成本效益：一项系统评价与经济分析
Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. doi: 10.3310/hta8180.
4
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.与非渐减紧密控制类风湿关节炎治疗相比，阿达木单抗和依那西普的疾病活动指导剂量优化是一种具有成本效益的策略：DRESS 研究的分析。
Ann Rheum Dis. 2016 Nov;75(11):1939-1944. doi: 10.1136/annrheumdis-2015-208317. Epub 2016 Jan 13.
5
Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.已缓解的类风湿关节炎患者使用肿瘤坏死因子阻滞剂的注射间隔的成本效益：来自类风湿关节炎试验中肿瘤坏死因子阻滞剂注射间隔的经济评估。
Value Health. 2017 Apr;20(4):577-585. doi: 10.1016/j.jval.2017.01.005. Epub 2017 Mar 10.
6
Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.两种逐渐减量策略在类风湿关节炎中的两年成本效益比较：TARA 试验的成本效用分析。
Ann Rheum Dis. 2020 Dec;79(12):1550-1556. doi: 10.1136/annrheumdis-2020-217528. Epub 2020 Sep 9.
7
Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.关于生物性改善病情抗风湿药（阿达木单抗、依那西普和英夫利昔单抗）在类风湿关节炎治疗中价值的八项药物经济学研究综述。
J Manag Care Pharm. 2006 Sep;12(7):555-69. doi: 10.18553/jmcp.2006.12.7.555.
8
Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.目前类风湿关节炎生物制剂成本效益评估中的不足之处。
Nat Clin Pract Rheumatol. 2009 Feb;5(2):78-9. doi: 10.1038/ncprheum0985. Epub 2008 Dec 23.
9
[Economic evaluation of a new treatment for rheumatoid arthritis].[类风湿关节炎新疗法的经济学评估]
Nihon Rinsho. 2007 Jul;65(7):1327-30.
10
The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.生物反应调节剂治疗类风湿关节炎的经济学评价中对照药物的选择问题。
Best Pract Res Clin Rheumatol. 2012 Oct;26(5):659-76. doi: 10.1016/j.berh.2012.07.012.

引用本文的文献

1
Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study.疾病活动度引导的剂量优化（包括类风湿关节炎中肿瘤坏死因子抑制剂的停用）长达10年有效：DRESS研究的观察性随访
Rheumatology (Oxford). 2025 Feb 1;64(2):533-540. doi: 10.1093/rheumatology/keae103.
2
An AI-Powered Clinical Decision Support System to Predict Flares in Rheumatoid Arthritis: A Pilot Study.一种用于预测类风湿关节炎病情发作的人工智能临床决策支持系统：一项初步研究。
Diagnostics (Basel). 2023 Jan 1;13(1):148. doi: 10.3390/diagnostics13010148.
3
Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
生物制剂 DMARDs 在非系统性幼年特发性关节炎患者中的停药：复发率及相关因素的范围回顾。
Pediatr Rheumatol Online J. 2022 Dec 5;20(1):109. doi: 10.1186/s12969-022-00769-5.
4
Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.预测指导下生物制剂治疗类风湿关节炎患者的药物减量（PATIO）：一项随机对照试验方案。
Trials. 2022 Jun 16;23(1):494. doi: 10.1186/s13063-022-06471-x.
5
Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions.利用真实世界数据动态预测类风湿关节炎生物 DMARDs 减量过程中的 flares：预测辅助决策的开发、验证和潜在影响。
Arthritis Res Ther. 2022 Mar 23;24(1):74. doi: 10.1186/s13075-022-02751-8.
6
Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.基于 FREE-J 研究中缓解期类风湿关节炎患者的共同决策选择治疗方案。
Rheumatology (Oxford). 2022 Nov 2;61(11):4273-4285. doi: 10.1093/rheumatology/keac075.
7
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.与标准银屑病治疗相比，阿达木单抗、依那西普和乌司奴单抗严格控制剂量减少策略的健康经济后果：CONDOR研究的成本效用分析。
Acta Derm Venereol. 2020 Dec 1;100(19):adv00340. doi: 10.2340/00015555-3692.
8
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.在银屑病关节炎和中轴型脊柱关节炎中 TNF 抑制剂的剂量减少和停药策略：一项实用的开放性标签、随机、非劣效性试验的设计。
Trials. 2020 Jan 15;21(1):90. doi: 10.1186/s13063-019-4000-5.